Wichterman Troy sold (to issuer) 256,000 shares of BLFS

Wichterman Troy (Chief Financial Officer) sold (to issuer) 256,000 shares of BIOLIFE SOLUTIONS INC (BLFS) on 2026-10-06.

Original reporting
SEC EDGAR · Wichterman Troy
Published Oct 9, 2026, 1:59 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 2:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLFS
Neutral
medium confidence
Mentioned
$BLFS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLFSNeutralLow
01

Why it matters

The CFO's complete divestiture may be interpreted as a negative signal, but the absence of price details limits market reaction.

02

Market read

A modest insider sell with no disclosed price; likely limited immediate trading impact.

03

What to watch

Lack of disclosed price prevents assessment of financial gain; CFO may have other non‑financial reasons.

Relevance 4/10Novelty 4/10Timing: filing date 2026-10-08

Background

Form 4 filings disclose insider transactions to the SEC, providing transparency on executive holdings.

Company-level read

Ticker impact

$BLFSNeutralMedium confidence
Context

CFO Troy Wichterman sold 256,000 shares of Biolife Solutions in a Form 4 filing, reducing his holdings to zero.

Expected impact

potential slight downward pressure as the market prices the insider sell

Evidence & confidence

Insider sales by senior executives can modestly affect sentiment, especially when the sale clears the insider's position.

Market effects

Minimal impact on the biotech sector; isolated insider transaction.

No broader regional effect.

Negligible.

Counterpoint

The sale could be a routine liquidity event unrelated to company outlook.

Key entities

  • Biolife Solutions Inc

    US-listed biotech firm (NASDAQ: BLFS).

  • Troy Wichterman

    Chief Financial Officer of Biolife Solutions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RGENHighAI 8/10

REPLIGEN CORP (RGEN): Completion of Acquisition or Disposition of Assets

REPLIGEN CORP (RGEN) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Repligen Corporation 41 Seyon Street Building #1, Suite 100 Waltham, Massachusetts 02453 REPLIGEN COMPLETES ACQUISITION OF BIOLIFE SOLUTIONS WALTHAM, MA - October 6, 2026 – Repligen Corporation (NASDAQ: RGEN, “Repligen”, or the “Company”), a life sciences company foc

$RGENHigh

BIOLIFE SOLUTIONS INC (BLFS): Completion of Acquisition or Disposition of Assets

BIOLIFE SOLUTIONS INC (BLFS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 2.01 Completion of Acquisition or Disposition of Assets. The information set forth in the “Explanatory Note” of this Current Report on Form 8-K is incorporated by reference into this Item 2.01. At the effective time of the First Merger (the “First Merger Effective Time”), ea

$RGENHighAI 8/10

Repligen Completes Acquisition of BioLife Solutions

Repligen Corporation (NASDAQ: RGEN) completed its acquisition of BioLife Solutions (NASDAQ: BLFS) for $11.25 per share in cash and 0.1442 shares of Repligen stock. The deal expands Repligen's presence in the cell therapy market, adding high-margin consumables and recurring revenue. BioLife's products support 18 approved therapies and most U.S. cell-based therapy trials. Repligen will discuss the transaction's financial impact on its Q3 2026 earnings call.

$FRSHHighAI 8/10

Freshworks to Replace BioLife Solutions in S&P SmallCap 600

S&P Dow Jones Indices announced Freshworks (FRSH) will replace BioLife Solutions (BLFS) in the S&P SmallCap 600 on October 8, 2026. Repligen (RGN) is acquiring BioLife for $1.5B, with BioLife shareholders receiving $11.25 per share in cash and 0.1442 shares of Repligen stock. Freshworks reported Q2 2026 revenue of $237.4M, up 16% YoY, and its first GAAP profitability in 2026.